Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)

Ann Oncol. 1991 Feb:2 Suppl 2:181-5. doi: 10.1007/978-1-4899-7305-4_29.

Abstract

Thirty-six successive adult patients with lymphoblastic lymphoma entered a study of sequential chemotherapy consisting of an intensive LSA2-L2-type protocol to induce first complete remission. Eighteen patients in first CR (median age 22 years, range 15-51), underwent autologous bone marrow transplantation after receiving a conditioning regimen consisting of cyclophosphamide and total body irradiation. Of these 18 patients, 2 were in stage III and 16 in stage IV; 15 showed mediastinal and 9 bone marrow involvement at diagnosis. The transplant procedure was well tolerated and no treatment-induced deaths occurred. At this time, 14 out of 18 patients are alive and well between 1 and 60 months post transplant (median follow-up time 46 months) with an actuarial disease-free survival of 74%. This phase II study suggests that high-dose chemo-radiotherapy followed by autologous bone marrow transplantation may improve long-term disease-free survival in advanced stage adult lymphoblastic lymphoma.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Lymphoid / mortality
  • Leukemia, Lymphoid / pathology
  • Leukemia, Lymphoid / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pancytopenia / etiology
  • Remission Induction
  • Survival Rate
  • Whole-Body Irradiation

Substances

  • Cyclophosphamide